CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma
Introduction:
The CLDN18 gene, encoding claudin 18.1 and claudin 18.2, is
a key component of tight junction strands in epithelial cells that form a paracellular barrier that is critical in Stomach Adenocarcinoma (STAD).
Methods:
Our study included 1,095 patients with proven STAD, 415 from The Cancer
Genome Atlas (TCGA) cohort and 680 from the Gene Expression Omnibus database.
We applied various analyses, including gene set enrichment analysis, pathway analysis,
and in vitro drug screening to evaluate survival, immune cells, and genes and gene sets
associated with cancer progression, based on CLDN18 expression levels. Gradient boosting machine learning (70% for training, 15% for validation, and 15% for testing) was
used to evaluate the impact of CLDN18 on survival and develop a survival prediction
model.
Results:
High CLDN18 expression correlated with worse survival in lymphocyte-poor
STAD, accompanied by decreased helper T cells, altered metabolic genes, low necrosis-related gene expression, and increased tumor proliferation. CLDN18 expression
showed associations with gene sets associated with various stomach, breast, ovarian,
and esophageal cancers, while pathway analysis linked CLDN18 to immunity. Incorporating CLDN18 expression improved survival prediction in a machine learning model.
Notably, nutlin-3a and niraparib effectively inhibited high CLDN18-expressing gastric
cancer cells in drug screening.
Conclusion:
Our study provides a comprehensive understanding of the biological role
of CLDN18-based bioinformatics and machine learning analysis in STAD, shedding
light on its prognostic significance and potential therapeutic implications. To fully elucidate the molecular intricacies of CLDN18, further investigation is warranted, particularly through in vitro and in vivo studies.
